New Malaria Treatment Gets First Approval for Use in Children
A new drug that can cure a certain type of malaria was approved in Australia Monday for kids and teens.
The approval was announced on Monday by the nonprofit Medicines for Malaria Venture (MMV), which helped develop the drug with GlaxoSmithKline (GSK). It is for a single dose of tafenoquine (Kozenis) for use in combination with the traditional malaria drug chloroquine. This is the first time the drug has been authorized for use in children and will likely lead to more such approvals worldwide.
Tafenoquine can cure a type of malaria caused by Plasmodium vivax, which is most common in South and Southeast Asia, South America and the Horn of Africa. P. vivax causes up to 5 million malaria infections every year. Children aged 2 to 6 are four times more likely than adults to contract it, MMV said.
"We are proud to have worked with GSK to develop this child-friendly treatment and are thrilled by today's announcement. P. vivax malaria is particularly dangerous for young children for whom repeated relapses can lead to cumulative severe anemia and, in some cases, be fatal. Today, we have a tool to put a stop to the relentless relapse both for adults and children -- we are one step closer to defeating this disease," Dr. David Reddy, CEO of MMV, said in a statement.
The drug will be submitted for approval in nine countries, as well as to the World Health Organization, George Jagoe, an executive vice president with MMV, told The New York Times.
In July 2018, the U.S. Food and Drug Administration approved 300 milligrams of tafenoquine for P. vivax malaria in patients 16 and older, and Australia, Brazil, Thailand and Peru followed suit with similar approvals, the Times reported.
The new drug for children is a single 50-milligram tablet dispersed in water, which is much easier to take than the seven- or 14-day course of pills for adults.
About 62% of the children studied experienced some side effects. While none of the side effects were severe, the treatment caused vomiting in about one in five children. At four months, the treatment was 95% effective at preventing recurrence.
Malaria is among the deadliest of infectious diseases and caused 627,000 deaths worldwide in 2020.
Most of these deaths are in sub-Saharan Africa, home to another form of the malaria parasite called Plasmodium falciparum. In October, the World Health Organization backed the first malaria vaccine, also made by GlaxoSmithKline, against P. falciparum.
Visit the U.S. Centers for Disease Control and Prevention for more on malaria.
SOURCES: The New York Times; Medicines for Malaria Venture, statement, March 14, 2022
Health News is provided as a service to Medicine Shoppe Ridgway site users by HealthDay. Medicine Shoppe Ridgway nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.
Copyright © 2022 HealthDay All Rights Reserved.